<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01410513</url>
  </required_header>
  <id_info>
    <org_study_id>TCD12012</org_study_id>
    <secondary_id>U1111-1119-2906</secondary_id>
    <nct_id>NCT01410513</nct_id>
  </id_info>
  <brief_title>Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for&#xD;
      SAR245409 when administered in combination with rituximab or bendamustine plus rituximab&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To determine the safety and tolerability of SAR245409 in combination with rituximab or&#xD;
           bendamustine plus rituximab in subjects with indolent Hon-Hodgkin Lymphoma (iNHL) Mantle&#xD;
           Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)&#xD;
&#xD;
        -  To determine the pharmacokinetics (PK) of SAR245409, bendamustine and rituximab when&#xD;
           used in combination in subjects with iNHL, MCL or CLL&#xD;
&#xD;
        -  To determine the pharmacodynamic (PD) effects of SAR245409 in combination with rituximab&#xD;
           or bendamustine plus rituximab in subjects with iNHL, MCL or CLL&#xD;
&#xD;
        -  To determine the antitumor activity of SAR245409 in combination with rituximab or&#xD;
           bendamustine plus rituximab in subjects with iNHL, MCL or CLL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will take SAR245409 twice daily. All subjects will receive SAR245409 as long as&#xD;
      there is clinical benefit.&#xD;
&#xD;
      Combination therapy with SAR245409, bendamustine and rituximab , will be administered over a&#xD;
      28 day cycle for up to 6 to 8 cycles.&#xD;
&#xD;
      Subjects receiving the doublet combination , SAR245409 plus rituximab will receive weekly&#xD;
      rituximab for 4 - 8 weeks. Monthly Rituximab may be continued beyond 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification Of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)</measure>
    <time_frame>4 weeks to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment emergent adverse events</measure>
    <time_frame>Time from receiving first dose of SAR245409 until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax) of SAR245409</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax) of SAR245409</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC0-12h) of SAR245409</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough) of SAR245409</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) of bendamustine</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUClast) of bendamustine</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ceoi) of bendamustine</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax) of bendamustine</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cl) of bendamustine</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Vss) of bendamustine</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC0-7h) of rituximab</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ceoi) of rituximab</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax) of rituximab</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as determined by objective response rate (ORR)</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>SAR245409 + rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR245409 + rituximab + bendamustine (iNHL, MCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR245409 + rituximab+ bendamustine (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR245409</intervention_name>
    <description>Pharmaceutical form:capsule Route of administration: oral</description>
    <arm_group_label>SAR245409 + rituximab</arm_group_label>
    <arm_group_label>SAR245409 + rituximab + bendamustine (iNHL, MCL)</arm_group_label>
    <arm_group_label>SAR245409 + rituximab+ bendamustine (CLL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  A confirmed diagnosis of indolent non-Hodgkin lymphoma, mantle cell lymphoma or&#xD;
             chronic lymphocytic leukemia&#xD;
&#xD;
          -  Evaluable disease or measurable disease&#xD;
&#xD;
          -  Transfusion independent&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  Male and Female subjects &gt; 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2&#xD;
&#xD;
          -  Women of childbearing potential using adequate contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior therapy with a PI3K, mTOR or dual PI3K/mTOR inhibitor resulting in adverse&#xD;
             events necessitating treatment discontinuation&#xD;
&#xD;
          -  Eligible for a hematopoietic stem cell transplant (HSCT)&#xD;
&#xD;
          -  The subject has received investigational or non-investigational cytotoxic chemotherapy&#xD;
             (i.e., cyclophosphamide), small molecule cancer therapy (i.e., imatinib), biologic&#xD;
             cancer therapies other than rituximab (i.e., alemtuzumab, cytokines, vaccines or other&#xD;
             monoclonal antibodies) hormonal therapy, radio- or immuno- conjugates (e.g.&#xD;
             ibritumomab tiuxetan, tositumomab) or immunosuppressants to treat malignancy within 4&#xD;
             weeks prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Radiation therapy within 2 weeks prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Autologous Hematopoietic Stem Cell Transplant (HSCT) within the past 16 weeks&#xD;
&#xD;
          -  Prior allogeneic HSCT&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases or leptomeningeal involvement&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody (anti-HCV)&#xD;
&#xD;
          -  Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV)&#xD;
             infection&#xD;
&#xD;
          -  Active peptic ulcer disease requiring treatment with proton pump inhibitors (e.g.&#xD;
             pantoprazole) or Type 2 histamine antagonists (e.g. cimetidine)&#xD;
&#xD;
          -  Diagnosis or treatment for another malignancy within 3 years of enrollment with the&#xD;
             exception of complete resection of basal cell or squamous cell carcinoma of the skin,&#xD;
             an in situ malignancy or low-risk prostate cancer after curative therapy&#xD;
&#xD;
          -  Inadequate bone marrow function&#xD;
&#xD;
          -  Abnormal liver function&#xD;
&#xD;
          -  Abnormal renal function&#xD;
&#xD;
          -  Abnormal coagulation&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2011</study_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

